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ABSTRACT
In head and neck squamous cell cancer (HNSCC), four intrinsic subtypes (or
groups) have been identified, and each one possesses a unique biology that will require
specific treatment strategies. We previously reported that mesenchymal (group 2)
tumors exhibit reduced levels of Trop2 expression. In this study, we investigated the
functional role of Trop2 in HNSCC and find that loss results in autocrine activation
of the EGFR family member ErbB3 via neuregulin-1. Trop2 localizes to both the cell
surface and cytosol of HNSCC cells and forms a complex with neuregulin-1, which
is predominantly cytosolic. Inactivation of Trop2 increases the concentration of
neuregulin-1 at the cell surface where it is cleaved to activate ErbB3. In primary
HNSCC, detection of ErbB3 activation was limited to Trop2 negative tumors. An
analysis of the Cancer Genome Atlas (TCGA) HNSCC dataset confirms enrichment
for ErbB3 activity in mesenchymal tumors. Notably, Trop2 loss triggers sensitivity to
anti-ErbB3 antibodies, which results in reduced proliferation and tumorigenic growth
of Trop2 negative HNSCC cancer cells. These results uncover a molecular mechanism
by which tumor cells control the amount of cell-surface neuregulin-1 available for
cleavage and ErbB3 activation. Moreover, we demonstrate that Trop2 is a potential
surrogate biomarker to identify tumors with ErbB3 activation and may therefore
respond to anti-ErbB3 therapeutics.

INTRODUCTION

biology: basal (Group 1), mesenchymal (Group 2), atypical
(Group 3) and classical (Group 4) [3]. HNSCC subtypes
have been found to possess unique biological features that
are associated with very different outcomes. For example,
basal tumors were reported to exhibit high EGFR pathway
activity, while mesenchymal tumors, which comprise
approximately twenty-five percent of HNSCC, exhibited
low EGFR activity; the atypical subtype was enriched in
human papillomavirus-related HNSCC; and the classical
subtype was shown to be enriched for genes associated
with exposure to cigarette smoke [2, 3]. Despite the recent

Head and neck squamous cell carcinoma (HNSCC)
is a highly heterogeneous disease whose behavior is
dictated by the site of origin within the head and neck as
well as the underlying etiology [1]. Molecular profiling
of these biologically heterogeneous tumors has revealed
four distinct subtypes [2]. Recently this classification was
validated by Walter, et al. and The Cancer Genome Atlas
(TCGA) Project in two independent tumor dataset [3, 4],
and the nomenclature has now been updated to reflect their
www.impactjournals.com/oncotarget
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validation of the HNSCC subtypes, much remains to be
learned concerning their biology before knowledge of the
subtypes will have an impact on clinical decision-making.
This situation lies in stark contrast to the successful
application of subtype information in other tumor types
such as breast [5] and colon [6] cancer, where molecular
subtyping guides the selection of targeted therapies as well
as the rational development of experimental therapeutics.
We recently reported that expression of Trop2, a
transmembrane protein that is emerging as a pleiotropic
mediator of growth and survival signals, is significantly
reduced or lost in mesenchymal HNSCC tumors [7].
Trop2 consists of a large extracellular domain, a singlepass transmembrane domain, and a twenty-six amino acid
tail. Oncogenic signaling can be initiated either by gainor loss-of-function depending on cell type and context.
Ectopic Trop2 expression was shown by our group as
well as others to promote tumor growth in NIH3T3 [8]
and pancreatic cancer [9] cells, respectively. Other studies
indicate a pro-tumorigenic consequence for Trop2 loss.
Using a skin carcinogenesis assay in a Trop2 knockout
animal, we showed that Trop2 deletion contributes to
squamous cell tumorigenesis [7]. More recently, it was
reported that the Trop2 gene locus is methylated in a
significant fraction of adenocarcinomas of the lung and
that this loss contributes to aggressiveness in that disease
[10].
The ErbB receptor family plays an important role
in HNSCC. Basal subtype tumors are suggested to signal
predominantly through epidermal growth factor receptor
(EGFR) [2]. Other ErbB family members – ErbB2
and ErbB3 – have also been reported to be commonly
expressed in HNSCC, but their significance and
relationship to subtype in HNSCC is less well established
[11-13]. Although members of this superfamily share
basic structural features, each one exhibits unique
properties that contextualize their signaling, diversify
the range of outputs, and determine patterns of response
to therapeutic inhibition [14]. No ligand for ErbB2 has
yet to be identified, but the gene is often amplified in
breast and gastric cancer and is potently oncogenic in
multiple experimental systems [15, 16]. ErbB3 (HER3)
is notable as the only EGFR family member that is unable
to homodimerize, and it also lacks strong intrinsic kinase
activity [17]. As such, it requires dimerization with and
transphosphorylation by its preferred partner, ErbB2, but
it can also dimerize with ErbB4, or EGFR, upon which
ErbB3 potently activates the PI3 kinase pathway [18].
The initiating signals that influence ErbB3 activation are
diverse and include post-translational modifications such
as translocation from intracellular stores [19]. Recently,
ligand-independent mutational activation of ErbB3
has been reported [20], but autocrine signaling via the
neuregulin (NRG) family of ErbB3 ligands remains the
most well established mechanism of ErbB3 activation [2123].
www.impactjournals.com/oncotarget

Neuregulins, like all EGF family ligands, are
generated as transmembrane precursor proteins.
Cleavage of the ectodomain is achieved by the ADAMs
(A disintegrin and metalloproteinase) family of zincdependent membrane-associated metalloproteinases
[23, 24], which release the active ligand. ADAMmediated cleavage can be regulated by oncogenes and
other intracellular signals such as protein kinase C [2527], but additional details of the molecular mechanisms
determining neuregulin release are limited. Herein, we
report a novel mechanism of NRG1 regulation involving
Trop2. NRG1 interacts with Trop2, and when Trop2 is
lost, an increase in surface expression of NRG1, NRG1
cleavage, and ErbB3 activation occurs. The relationship
between low Trop2 expression and elevated ErbB3
activation was also observed in primary HNSCC tumors,
and importantly, we demonstrate that Trop2 loss confers
sensitivity to ErbB3 antibodies in tumor xenografts
derived from HNSCC cells.

RESULTS
To investigate the relationship between Trop2 loss
and signaling in HNSCC, we examined the effects of
reducing Trop2 levels in head and neck squamous cancer
cells. Using two short-hairpins targeting unique regions
of the Trop2 coding sequence, Trop2 levels were first
reduced in the SCC-1 oral squamous cell cancer cell
line (Figure 1A&C). As Trop2 resides in large part at the
cell surface (in addition to the cytosol), we reasoned that
Trop2 is likely to modify signals originating at the plasma
membrane and chose to globally interrogate signaling
changes caused by Trop2 loss using an unbiased phosphoproteomic approach. Therefore, using an antibody array
that simultaneously captures the signaling status of fortytwo transmembrane receptor tyrosine kinases, many of
which are implicated in tumor biology, we measured the
effects of Trop2 loss on phosphorylated (activated) forms
of these proteins. Protein lysates from SCC-1 control and
knockdown cells were generated and exposed to antibody
arrays. Strikingly, the only receptor whose activation was
observed to increase upon Trop2 loss was ErbB3 (Figure
1B), a member of the ErbB family implicated in several
aspects of aggressive tumor behavior [28-30]. No increase
in signaling in any other ErbB family members or other
pathways such as IGF-1R was detected after Trop2 loss.
Interestingly, the p-Met signal is significantly attenuated
after Trop2 loss, possibly due to a negative feedback
mechanism (Supplementary Figure 1).
To confirm that Trop2 loss induces ErbB3 activation
in HNSCC cells, we measured the levels of p-ErbB3
levels after Trop2 depletion in SCC-1, SCC-25, and Cal
27 cells by immunoblot analysis. Consistent with the
result observed on the antibody array, when Trop2 protein
expression was reduced, ErbB3 became activated as
revealed by Tyr1289 phosphorylation using a phospho9282
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specific antibody (Figure 1C &D, Supplementary Figure
2A). In addition, downstream signaling to AKT was also
increased upon Trop2 loss as judged by immunoblots
against Ser473 phosphorylation on AKT. To rule out
the possibility that the observed Trop2 loss-induced
ErbB3 activation was caused by an off-target effect from
RNA interference, we further investigated the specific
contribution of Trop2 to ErbB3 activity. An RNAiresistant Trop2 cDNA was engineered by generating
silent mutations in the cognate sequence targeted by the

vector shTrop2.1. Upon lentiviral transduction of this
plasmid into SCC1-shTrop2.1 cells, Trop2 re-expression
was able to reduce ErbB3 and AKT activation (Figure 1E).
In a parallel experiment, we transduced a Flag-epitope
tagged Trop2 cDNA into parental SCC-1 cells and found
it capable of suppressing basal levels of p-ErbB3 and
subsequent AKT activity (Figure 1F). Collectively, these
results suggest that Trop2 can function as an inhibitor of
ErbB3 activity.
Next, we sought to determine whether an inverse

Figure 1: Trop2 Loss Promotes ErbB3 Activation in HNSCC Cells. A. Immunofluorescence images of Trop2 staining (green) in

SCC1 HNSCC cells after stable knockdown using short hairpins targeting the Trop2 cDNA. Nuclei are counterstained with 4’6-diamidino2-phenylindole (DAPI). B. Results of a phosphorylated receptor tyrosine kinase antibody array demonstrating elevated p-ErbB3 in lysates
from Trop2 knockdown SCC1 cells. The exposures were normalized to the control spots (four corners), which exhibit equal intensities.
C&D. Representative immunoblots showing hyperactivation of ErbB3 and AKT caused by Trop2 loss in SCC1 and SCC25 HNSCC cells.
Two short hairpins targeting distinct regions of the Trop2 cDNA were used. E. Reduction of ErbB3 activity after ectopic expression of an
RNAi-resistant Trop2 cDNA in Trop2 knockdown SCC1 cells. Arrow points to the lower band which is the correct size for Trop2. F. Ectopic
expression of a Flag-epitope tagged Trop2 cDNA in SCC1 cells suppresses basal ErbB3 and AKT activation. Control is an empty vector.
Relative increases in phosphoproteins in control versus experimental groups were quantified by photodensitometry after normalization to
total ErbB3 or AKT protein which served as an internal controls. Immunoblots are representative of at least three independent experiments.
Significance was measured by student’s t test, * (P<0.05), ** (P<0.01), *** (P<0.001).
www.impactjournals.com/oncotarget
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correlation between Trop2 and NRG1-ErbB3 pathway
activation could be identified across tumors from HNSCC
patients. Ideally, we would have liked to determine
whether NRG1 is cleaved in the absence of Trop2 in
tumor samples, but cleavage specific antibodies are not
available and the multiple variant isoforms of NRG1 exist
further making such an approach ambiguous. Therefore,
to judge the relationship between activation of the
NRG1-ErbB3 pathway and Trop2 expression, we chose
to measure the presence of ErbB3 phosphorylation and
correlate this with Trop2 status. We reasoned that tumors
that are predominantly Trop2 positive would have minimal
evidence of p-ErbB3 expression, and conversely, those
with less Trop2 expression would exhibit more p-ErbB3
staining. To address these issues, we obtained thirty-nine
freshly cut sections of primary HNSCC and examined

multiple regions of each section. P-ErbB3 expression was
not observed in any of the thirty-one tumors that showed
uniform Trop2 expression. We never observed a signal for
p-ErbB3 in any Trop2 positive cells although total ErbB3
expression was found to be comparable in Trop2 positive
and negative tumors (Supplementary Figure 3). In contrast,
tumors that were Trop2 negative were the only ones to
show evidence of p-ErbB3 staining (P=0.0001, Figure
2A-G, Supplementary Figure 3). Hence, in accord with
the observation that Trop2 loss triggers ErbB3 activation
in cell culture models of HNSCC, ErbB3 activation is
inversely correlated with loss of Trop2 expression in
primary HNSCC.
To investigate the relationship between Trop2 and
p-ErbB3 in a larger cohort of tumors, we analyzed TCGA
dataset. Unfortunately, protein expression for Trop2 is

Figure 2: Inverse Correlation Between Trop2 and p-ErbB3 in Primary HNSCC. Enumeration of ErbB3 positive or negative
tumors as a function of Trop2 staining reveals an inverse correlation significant to P=0.0001 (Fisher’s exact test). Immunohistochemical
staining of a representative squamous cell cancer showing membrane expression of p-ErbB3 (B) and absence of Trop2 expression in
an adjacent section (C) in a tumor section showing poorly differentiated squamous histology after hematoxylin and eosin staining (D).
Immunohistochemical staining of a representative squamous cell cancer showing absence of p-ErbB3 expression (E) and increased Trop2
expression in an adjacent section (F) in a tumor showing well-differentiated histology after hematoxylin and eosin staining (G). Images are
photographed at 20x power.
www.impactjournals.com/oncotarget
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not available, and therefore we correlated Trop2 mRNA
expression with total and p-ErbB3 protein expression.
We previously reported that Trop2 mRNA expression is
reduced in the mesenchymal group of tumors [7], which
represented approximately twenty-five percent of the
total number of tumors from the Chung dataset [2]. We
confirmed the association between low Trop2 mRNA
expression and the mesenchymal subtype in TCGA (logfold change -1.1, P= 5x10-13), where the mesenchymal
subtype represents twenty-four percent of tumors (Figure
3). Next, we analyzed ErbB3 signaling as a function of
HNSCC subtype using the TCGA reverse phase protein
array (RPPA) data. In this analysis, we found that both
total ErbB3 and p-ErbB3 (pY1298) were expressed at
higher levels in the mesenchymal subtype compared to
the other subtypes (log-fold change 0.6, P=7x10-4 for total
ErbB3, and log-fold change 0.6, P=9x10-4, for p-ErbB3).
These data confirm the relationship between low Trop2
expression and enrichment for ErbB3 activity that we
initially observed in our functional studies of Trop2 loss.
To elucidate the mechanism responsible for Trop2loss induced ErbB3 activation, we first examined whether
basal p-ErbB3 levels in control SCC1 cells are sensitive
to removal of growth factor. We observed that after two
hours of serum starvation, levels of ErbB3 activity were
reduced by over one-half in shLacZ control cells (Figure
4A). We then examined whether the heightened ErbB3

activity in Trop2 knockdown cells was also sensitive to
growth factor deprivation, and observed a similar level
of reduction of p-ErbB3 in these cells as was observed
in shLacZ control cells. To further investigate the role of
growth factors in Trop2-loss induced p-ErbB3 activation,
we asked whether reducing Trop2 levels results in the
secretion of an ErbB3-activating ligand that could replace
the ability of growth factor-containing serum to stimulate
ErbB3 activity in shLacZ control cells. To address this
question, we reasoned that shLacZ-bearing control SCC-1
cells, which exhibit a low level of basal ErbB3 activity,
could serve as a system to assay for a putative soluble
ligand. We generated conditioned media from Trop2
knockdown and control cells by growing cells in serumfree media for twenty-four hours and added this media to
the different cell populations that had been serum starved
for two hours. Importantly, only conditioned media from
Trop2 knockdown cells was able to activate serum-starved
shLacZ control cells, indicating release of an ErbB3stimulating ligand upon Trop2 loss (Figure 4A). Next we
sought to determine the identity of the ligand responsible
for this activity. As neuregulins are the only ligands
known to activate ErbB3 and NRG1 has been reported
to be expressed in a subset of HNSCC tumors [12], we
considered that this family member would be a likely
candidate for regulation by Trop2. We therefore measured
the effects of reducing Trop2 levels on soluble and full-

Figure 3: Inverse Correlation Between Trop2 and p-ErbB3 as a Function of HNSCC Subtypes in the TCGA HNSCC
Dataset . Box and whisker plots of Trop2 expression (left panel) and total and p-ErbB3 protein expression by RPPA (middle and right
panels respectively), as functions of Chung and TCGA subtype calls. The data reveal increased total and p-ErbB3 activation in the
mesenchymal (group 2, Trop2-low) subtype.
www.impactjournals.com/oncotarget
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length NRG1. Using an antibody that recognizes the
amino terminus of NRG1, significantly increased NRG1
ectodomain protein levels were identified in concentrated
media taken from Trop2 knockdown SCC1 cells. Similar
results were obtained in Trop2 knockdown SCC25 and
Cal 27 cells (Figure 4B and Supplementary Figure 2B).
Interestingly, we did not observe an increase in levels
of full length cellular NRG1 upon Trop2 knockdown
despite observing increased NRG1 in the media (Figure
4B), suggesting that Trop2 is regulating NRG1 secretion

rather than production or destruction. Conversely,
overexpression of a Flag epitope-tagged Trop2 cDNA
in SCC1 cells significantly reduced the basal levels of
released NRG1 relative to levels in control SCC1 cells
harboring an empty vector (Figure 4C). To determine
whether NRG1 is required for the increased ErbB3 activity
observed upon Trop2 loss, we simultaneously depleted
Trop2 and NRG1 in HNSCC cells. We tested five NRG1
short hairpins, but only one, shNRG1.2, significantly
reduced NRG1 levels. Using this hairpin, we found that

Figure 4: Trop2 Loss Activates ErbB3 Through NRG1. A. Serum-free conditioned media from Trop2 knockdown cells stimulates
ErbB3 activity in SCC1 cells. Cells grown in serum-free media for two hours show decreased ErbB3 activity by immunoblot analysis (lanes
1 vs. 2 and 5 vs. 6) that is increased after two hour exposure to conditioned media (C.M.) from Trop2 knockdown cells (shown in lanes 4
and 8) but not by conditioned media from shLacZ control knockdown cells (shown in lanes 3 and 7). Media was conditioned for twenty-four
hours prior to harvest. B. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media
or whole cell lysates (W.C.L.) taken from Trop2 knockdown or LacZ control cells. Blots show increased NRG1 secretion but no change
in cellular full length NRG1 (FL NRG1) in the absence of Trop-2. Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot
analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an
empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression. Trop2 overexpression lane is
normalized to vector control values. D. Immunoblot analysis showing that NRG1 knockdown in Trop2-depleted cells suppresses Trop2loss induced ErbB3 activation. FL NRG1 is full length NRG1. Significance was measured student’s t test, * (P<0.05), ** (P<0.01), ***
(P<0.001).
www.impactjournals.com/oncotarget
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NRG1 depletion significantly reduced p-ErbB3 levels in
Trop2 knockdown cells, indicating an essential role for
NRG1 in this process (Figure 4D). Collectively, these data
point to a role for Trop2 in modulating autocrine ErbB3
activation by titrating the amount of NRG1 that is released
from its precursor form.
We then considered possible ways by which
Trop2 might modulate NRG1 release. Neuregulins
localize to cytoplasmic and nuclear pools depending
on cell type [31], and are brought to the cell surface
and exist as transmembrane precursor proteins prior to
cleavage and release of the ectodomain at the plasma

membrane. Consistent with these reports, by indirect
immunofluorescence staining we found NRG1 to be
primarily intracellular in SCC1 cells, visible in both
cytosolic and nuclear compartments (Supplementary
Figure 4). Given these observations, we investigated
whether the absence of Trop2 increases the cell surface
concentration of NRG1, which would provide a
mechanism of increased NRG1 cleavage and release upon
Trop2 loss. To test this possibility, we suppressed NRG1
cleavagewith batimastat, an ADAM17 inhibitor, so as to
be able to measure the contribution of Trop2 loss on static
levels of NRG1 on the cell surface. After Trop2 depletion

Figure 5: Functional and Physical Interaction Between Trop2 and NRG1. A. Membrane biotinylation and streptavidin

immunoprecipitation (IP) reveals an accumulation of cell-surface NRG1 (full length) in Trop2 knockdown SCC1 cells once cleavage is
suppressed by batimastat (twenty-four hour treatment). B. Immunblot analysis of biotinylated, streptavidin-precipitated membrane and
flow-through cytosolic protein fractions isolated from SCC1 cells after Flag-epitope tagged Trop2 overexpression showing a dramatic
increase in cytosolic concentrations of both Trop2 (anti-Flag antibody) and full-length NRG1. C. Immunoprecipitation of NRG1 followed
by anti-Flag immunoblot of lysates isolated from cells harboring an empty vector or Flag epitope-tagged Trop2 cDNA reveals an interaction
with Trop2 (left panel). The converse experiment (right panel) showing immunoprecipitation using anti-Flag antibodies followed by antiNRG1 immunblot also reveals the NRG1-Trop2 interaction. D. Immunoprecipitation of NRG1 (left panel) or endogenous Trop2 (right
panel) followed by immunoblotting of protein lysates from shLacZ or shTrop2.1 cells using the converse antibodies confirms the NRG1Trop2 complex. Trop2 knockdown cells serve as a negative control. Results are representative of three independent experiments.
www.impactjournals.com/oncotarget
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in SCC1 cells, we isolated the plasma membrane fraction
of cellular proteins by cell-surface biotinylation followed
by streptavidin immunoprecipitation, and immunoblotted
for NRG1. Strikingly, only in batimastat-treated Trop2
knockdown cells did an increase in membrane-associated,
full-length NRG1 become apparent (Figure 5A).
Next, we examined the effects of ectopic Trop2
overexpression on NRG1 localization; Trop2 localizes to
both the membrane and cytoplasm (Supplementary Figure
5) and we asked whether increasing Trop2 concentrations
in either of these locations would accordingly increase
the resident amount of NRG1. We again performed cell-

surface biotinylation and streptavidin immunoprecipitation
to examine membrane concentrations of Trop2 and NRG1,
and also examined the effects of increased Trop2 on the
cytoplasmic pools of NRG1 by cytosolic fractionation
(Figure 5B). Ectopic Trop2 expression increased Trop2
levels in both in membrane and cytosolic fractions, and
NRG1 levels were also comparably elevated in these
compartments relative to cells infected with an empty
vectorŠ. Taking the effects of both gain- and loss-of
function of Trop2 on NRG1 localization into account,
these data suggest that Trop2 sequesters NRG1 and
may influence its trafficking to or from the cell surface.

Figure 6: Trop2 Loss Confers Dependency on ErbB3. A. Immunblot analysis of decreased p-ErbB3 in Trop2 knockdown HNSCC

cells after four days of treatment with anti-ErbB3 antibodies (DL3.6b). B. Quantification of cell proliferation after seven days of antiErbB3 treatment shows reduced proliferation only in Trop2 knockdown cells. Cell proliferation in LacZ controls was unaffected (not
shown). Numbers were normalized to untreated cells. Columns mean, bars SE. (*,P<0.01 Fisher’s exact test). C. The anti-ErbB3 antibody
has a specific effect against Trop2-low, ErbB3-activated SCC1 cells. N=5 mice/group. Mice received 25mg/kg antibody weekly for four
weeks. P<0.0001, ANOVA.
www.impactjournals.com/oncotarget
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To develop insight into how this might occur, we
sought evidence of a NRG1-Trop2 protein interaction.
We immunoprecipitated endogenous soluble NRG1 in
Trop2-Flag expressing cells, immunoblotted resolved
proteins with anti-Flag antibodies, and observed evidence
of NRG1-Trop2 complex formation (Figure 5C).
Immunoprecipitation of protein lysates from these cells
with the anti-Flag antibody further revealed evidence
of a NRG1-Trop2 complex. In addition, when either
NRG1 or endogenous Trop2 was immunoprecipitated
from cells expressing the control hairpin, the existence
of a NRG1-Trop2 complex was also observed, and
immunoprecipitations from the knockdown cells served
as negative controls (Figure 5D). Lastly, using the RNAiresistant Trop2 cDNA as a template, we constructed Trop2
mutants harboring a deletion in either the EGF-like or
thyroglobulin type-1 domains present in the extracellular
region, both of which are required by Trop2 to bind IGF1 in lung cancer cells [10]. Similar to this requirement,

deletion of either domain abolishes the Trop2 interaction
with NRG1, and importantly, eliminates the ability of the
mutants to suppress ErbB3 activity in Trop2 knockdown
cells (Supplementary Figure 7). Collectively, these results
indicate that Trop2 is part of a complex with NRG1, and
suggest that Trop2 loss increases NRG1 accessibility to
the membrane-bound cleavage machinery.
Tumors can become addicted to the oncogenic
signaling stimulated by ErbB3 activation [12, 32], a
situation reminiscent of the addiction to Ras and other
oncogenes that occurs in other cancers. In particular,
tumors in which NRG1 triggers ErbB3 signaling have been
found to be sensitive to anti-ErbB3 antibody treatment
[33]. Based on these observations, we considered that if
NRG1 is in fact critical for Trop2-loss induced ErbB3
activation, then interfering with the NRG1-ErbB3 axis
should exert an inhibitory effect that is specific to Trop2
knockdown cells. To test this possibility, we measured the
effect of treatment with an anti-ErbB3 antibody (a gift

Figure 7: Model of Trop2 Regulation of NRG1. A. NRG1 is predominantly a cytosolic protein and interacts with Trop2, which
resides both in the cytosol and membrane pools. It is unknown whether Trop2 and NRG1 interact at the membrane and whether there
are pools of the complex that transit to and/or from the membrane. The yellow ellipses represent endosomes. B. Trop2 loss results in a
subsequent accumulation of NRG1 at the cell surface where it can be cleaved and released.
www.impactjournals.com/oncotarget
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from Genentech) on proliferation in vitro. Equal numbers
of cells were seeded in tissue culture dishes, exposed to
treatment with antibody for one week, harvested, and cell
numbers assayed. Anti-ErbB3 antibodies can block ligand
binding, receptor activation, and induce downregulation
[33], and the latter two phenomena were readily detectable
in Trop2 knockdown cells treated with the anti-ErbB3
antibody within four days of treatment (Figure 6A).
Importantly, the loss of ErbB3 activity in Trop2 depleted
cells was associated with a decrease in cell number when
enumerated after seven days of treatment (Figure 6B),
results that suggested to us that anti-ErbB3 antibodies
would also be useful to treat tumors in which Trop2 loss
stimulates the NRG1-ErbB3 axis. To determine if this is
the case, we performed a proof-of principle experiment
by evaluating the effects of treatment with the anti-ErbB3
antibody on tumor xenografts derived from control or
Trop2 knockdown SCC-1 cells. Trop2 knockdown cells
exhibit a small growth advantage over control cells when
grown as tumor xenografts in immunocompromised mice,
but this increase is not statistically significant (data not
shown). However, when xenografts were allowed to grow
to 400 mm3 in size prior to weekly antibody treatment,
the potent and specific anti-tumor properties of the
ErbB3 antibodies against the tumors lacking Trop2 was
revealed. These tumors ceased to grow within one week
of treatment, and failed to grow for the duration of the
four week experiment. In stark contrast, no anti-tumor
effect was observed in control cells (Figure 6C). Together,
the in vitro and in vivo data indicate that anti-ErbB3
antibodies are likely to have potent anti-tumor properties
against cancers that exhibit low Trop2 and high p-ErbB3
expression.

study of primary tumors from our institution, combined
with the functional data shown herein point to strong
correlations between the mesenchymal subtype, low Trop2
expression, and elevated ErbB3 activity.
Recent studies show that both gain- and lossof-function of Trop2 can activate oncogenic signaling
depending on context [7, 10, 36, 37], however, the ability
of Trop2 to influence NRG1 trafficking and release is an
unexpected finding. Although modulation of the level of
NRG1 cleavage by titration of ADAM17 activity is well
established (reviewed in [23, 38]), little is known about
how the growth factor itself is regulated independent of
ADAM17 activity. Interest in understanding how NRG1
is regulated is growing now that the role of ErbB3 as a
mediator of treatment resistance and aggressiveness is
becoming widely recognized [19, 39]. One report argues
for modulation of NRG1 expression at the level of
transcription in some HNSCC tumors [12]. More recently,
another layer of regulation, namely phosphorylation
of NRG1 by protein kinase C (PKC) prior to cleavage,
has been documented [27]. The ability of Trop2 to
influence NRG1 trafficking and cleavage now adds
another layer of regulation. We note that how Trop2 loss
results in increased cell-surface NRG1 is unclear. One
possibility, our favored model, is that Trop2 functions
as an intracellular retention factor for a distinct pool of
NRG1 that is otherwise destined to transit to the cell
surface (Figure 7A&B). Alternatively, Trop2 could recycle
ambient cell-surface NRG1 such that only in the absence
of Trop2 is NRG1 retained at the membrane long enough
to be cleaved and released.
The observations reported herein that tumors lacking
Trop2 exhibit heightened ErbB3 activity have important
clinical implications. The use of ErbB3 pathway inhibitors
as anti-cancer therapeutics is an area of active clinical
investigation, but the range of susceptible target tumors
is unknown. Previous work has demonstrated that liganddependent ErbB3 activation renders tumors susceptible to
anti-ErbB3 antibodies [33], and our observation that the
anti-ErbB3 antibody can suppress both proliferation and
tumorigenic growth of ErbB3 activated cells is consistent
with these findings. While the relationship between NRG1
expression and outcome in primary HNSCC has not been
reported to our knowledge, elevated expression of ErbB3,
a possible surrogate for activity, has been associated
with a poor prognosis in a variety of cancer types [2830]. Based on an analysis of NRG1 and ErbB3 mRNA
in recurrent HNSCC, post-treatment, late stage disease
also appears to be enriched for NRG1-mediated ErbB3
activation [40]; whether Trop2 loss is a mechanism for
autocrine activation of ErbB3 in this context remains to be
evaluated. Should this be the case, Trop2 could prove to
be a useful biomarker for ErbB3 activation and therapeutic
stratification in the setting of recurrent HNSCC, an
incurable disease for which treatment options are limited.
We also note that not all Trop2 negative tumors were found

DISCUSSION
For numerous tumor types, the identification of
specific molecular features that define intrinsic subsets
has dramatically improved the ability to predict the
efficacy of many targeted therapies and has facilitated the
rational development of novel therapeutics. The treatment
of HER2Neu amplified breast cancer with trastuzumab
and b-Raf mutant melanoma with vemurafenib are two
examples where subtyping has had a transformative
impact [34]. The power of subtyping, whether it is
based on genomic or epigenetic signatures, lies in the
identification of the underlying biology that drives the
subset of cancers, allowing for tailored and targeted
treatments. Unfortunately, subtyping in HNSCC has yet
to be integrated into the treatment of this disease. The use
of cetuximab in HNSCC exemplifies these deficits: its
efficacy is limited to a minority of patients and no tumor
characteristics have been identified and adopted to select
for these patients [35]. Our published analysis of the Chung
dataset [7], the currently presented analyses of TCGA
dataset, and the results from our immunohistochemical
www.impactjournals.com/oncotarget
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to be positive for p-ErbB3 expression. This observation is
could be due to a subgroup of Trop2 negative HNSCC
for which ErbB3 signaling is dispensible; also possible
is that clinical tumor procurement procedures are not yet
optimized for capturing the presence of phospho-proteins
which are known to be highly labile.
The mechanisms governing Trop2 expression
are also not well understood. We note that Trop2
overexpression has been reported in some tumors,
including HNSCC [37, 41]; however, we and others
have reported high-level basal expression of Trop2 in
normal epithelia of the tonsil and oral cavity, as well as
other stratified squamous epithelia [7, 42]. Therefore, the
significance of these other findings remains unclear. The
recent identification that Trop2 is subjected to regulated
intramembrane proteolysis in prostate cells suggests that
in some contexts, Trop2 regulation may be a dynamic
process [36]. In contrast, Trop2 has been reported to be
inactivated by methylation in some lung cancers [10],
motivating us to begin to investigate the methylation status
of the Trop2 promoter in tumors from TCGA dataset.
Ongoing studies such as these are designed to further
characterize the molecular details and dependencies
arising in the mesenchymal subset of HNSCC.
To conclude, we have identified a direct link
between Trop2 and NRG1-ErbB3 signaling in a subset
of HNSCC. These data provide a foundation for further
functional studies of NRG1 trafficking as well as Trop2
biology. In addition, more extensive genomic and
proteomic analyses of Trop2-low HNSCC will likely
uncover additional information that will be useful to
unravel the molecular basis of aggressive epithelial
tumorigenesis. Most importantly, the work described
herein delineates a framework for near-term clinical
studies of ErbB3 inhibitors against a group of tumors for
which these inhibitors are likely to have a high chance of
success.

Washington
University):
GCGCACGCTCATC
TATTACCT (nucleotides 1377-1397, ShTrop2.1).
CGTGGACAACGATGGCCTCTA (nucleotides 906-926,
ShTrop2.2). A short hairpin targeting lacZ was used as a
negative control (provided by S.A. Stewart, Washington
University in St. Louis). RNAi (1377) resistant hTrop2
sequence is 5’-gcgcacgctgatatactacct, which contains
four nucleotides with silent point mutation in RNAi
target region using Stratagene Quick Change II Site
Mutagenesis Kit. The NRG1 short hairpin sequence is
GCCTCAACTGAAGGAGCATAT. Lentivirus infection
was performed as described previously [8]. After infection,
cells were selected in puromycin.

Phospho-receptor tyrosine kinase array
The phospho-RTK array (R&D Systems)
specifically screens for membrane associated receptors.
Antibodies against 42 different RTKs were pre-spotted in
duplicate on nitrocellulose membranes. Cell lysates from
SCC1 ShLacZ and ShTrop2 cells were incubated with the
membrane according to the manufacturer’s instructions.
Thereafter, a pan anti-phosphotyrosine antibody was used
to detect the phosphorylated tyrosine on activated RTKs.
The blots were also developed using the ECL method.

Immunoblotting and Immunoprecipitation
Cells were lysed and homogenized with RIPA
lysis buffer with protease inhibitors. Antibodies used
in western blotting include: rabbit anti-phospho-AKT
(#4060, Ser473, Cell Signaling), rabbit anti-phosphoHER3 (#4791, Tyr1289, Cell Signaling) and mouse or
rabbit anti-ErbB3 (Santa Cruz Biotechnology), rabbit
anti-NRG1 (Santa Cruz Biotechnology), mouse antiNRG1 (MAB377, R&D Systems), goat anti-human Trop2
(AF650, R&D Systems), anti-ZO-1 (Life Technologies).
The immunoblots were developed using the ECL method
(Thermo Scientific).
For immunoprecipitation, cells were scraped off the
plates and washed with PBS. Lysis buffer (25mM Tris-Cl,
PH 7.5, 225mM NaCl, 5% Glycerol, 1mM EDTA, 25mM
NaF, 0.5% NP-40) with protease inhibitor cocktail (SigmaAldrich) was used to resuspend the cells. Cell lysates were
rocked at 4 ºC for 20 minutes. The insoluble fraction was
removed by centrifugation at 12,000g for 5 minutes. 500
μg of total protein was used and anti-NRG1 antibody
(MAB377, R&D Systems) or anti-Trop2 antibody (AF650,
R&D Systems) was added to the cell lysate for overnight
incubation at 4 ºC, then protein G beads were added,
and rocked 2-4 hours. 15 μg of protein from the whole
cell lysate was resolved and blotted as a loading control.
The beads were washed with lysis buffer four times and
proteins resolved by SDS-PAGE. Biotinylation was
performed according to the manufacturer’s instructions

MATERIALS AND METHODS
Cell culture
UM-SCC1 (provided by University of Michigan),
SCC25, and Cal 27 (both from ATCC) were grown
in DMEM/F12 containing 10% FBS. Cell lines were
authenticated and matched in February 2013 to short
tandem repeat DNA using the Johns Hopkins University
Fragment Analysis Facility.

RNA Interference
Stable short hairpins targeting human Trop-2
cDNA with the following sequences were cloned into the
lentiviral vector pLKO-puro (provided by S.A.Stewart,
www.impactjournals.com/oncotarget
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(Pierce, Thermo Scientific).

analyses were performed on the subset samples reserved
for publication for which RPPA measurements were also
available as of March 26, 2014.

Immunofluorescence, Immunohistochemistry, and
Tissue Samples and Processing
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